Health indices were flat on Monday as investors speculated about Tysabri for Crohn's disease, treatments for menopause symptoms and RNAi therapeutics.
Biogen(BIIB Quote) and Elan(ELN Quote) investors appeared nervous Monday in light of the upcoming Food and Drug Administration panel review of Tysabri for Crohn's disease. Regulators are worried that the drug's benefits for Crohn's may not outweigh its risks.
Tysabri was taken off the market in 2005 when a small group of patients developed PML, a rare and usually fatal viral disease that occurs almost exclusively in patients with severe immune deficiency. It was put back on the market in 2006 for multiple sclerosis, but it can't be taken in combination with other immune-suppressing drugs. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,337.05 | 1,095.94 | 2,183.73 | 34.23 |
Oil *
72.45
|
|
UP
51.08
|
UP
4.01
|
UP
10.74
|
UP
0.31
|
10 Yr
3.42%
SPDR Gold
110.84
|
|
+0.50%
|
+0.37%
|
+0.49%
|
+0.91%
|
Data delayed 20 minutes |
Connect with TheStreet